Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Capecitabine In Combination With Docetaxel Vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer

This study has been terminated.
Sponsor:
Information provided by:
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00087620
First received: July 12, 2004
Last updated: December 15, 2005
Last verified: December 2005
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given